UniQure, CSL's Haemophilia B Gene Therapy Hits Main Goal of Phase III Study

UniQure, CSL's Haemophilia B Gene Therapy Hits Main Goal of Phase III Study

FirstWord Pharma

Image

Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, Freeline Therapeutics Limited, Pfizer Inc., Shire, Spark Therapeutics, and uniQure, Inc.

Essential SSL